Policy & Regulation
Imfinzi approved in EU as first perioperative immunotherapy for muscle-invasive bladder cancer
4 July 2025 - Global biopharmaceutical company AstraZeneca (LSE/STO/NASDAQ:AZN) announced on Friday that it has received European Union approval for Imfinzi (durvalumab) as the first and only perioper...
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
4 July 2025 - Chinese biopharmaceutical company Akeso Inc (HK:9926) announced on Thursday the successful enrolment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibod...
Brii Biosciences enters BRII-693 licensing agreement with Joincare Group in Greater China
4 July 2025 - Chinese biotechnology company Brii Biosciences Limited (HK:2137) announced on Thursday that it has entered into a licence and technology transfer agreement with China-based Joincare Phar...
Neurizon enters global license agreement with Elanco to commercialise NUZ-001
3 July 2025 - Neurizon Therapeutics Limited (ASX: NUZ & NUZOA), an Australian clinical-stage biotech company, announced on Wednesday that it has executed an exclusive global license agreement with...
Ascletis doses first US participants in ASC30 Phase IIa study for obesity treatment
3 July 2025 - Ascletis Pharma Inc. (HKEX: 1672), a China-based pharmaceutical company, announced on Wednesday that the first participants with obesity or overweight with at least one weight-related co...
Jacobio's JAB-8263 Phase I/II Clinical Trial IND application receives Chinese regulatory approval
3 July 2025 - Jacobio Pharma (1167.HK), a China-based pharmaceutical company, announced on Wednesday that it has submitted the Phase I/II Investigational New Drug (IND) application for its BET inhibit...